Corporate Snapshot – Zhejiang Shapuaisi Pharmaceutical Co., Ltd. (603168.SS)
Zhejiang Shapuaisi Pharmaceutical, a Shanghai‑listed specialist in ophthalmic therapeutics, maintained a neutral trading profile on Wednesday, 21 March, closing flat at 0 % during the 24‑hour period ending at 11:46 AM Central Europe. The stock traded at approximately CNY 5.80 on primary exchanges, a modest increase from its 200‑day simple moving average of CNY 5.48, yet still below the 52‑week high of CNY 8.81 recorded on 12 January 2025. The 52‑week low, CNY 4.55, was reached on 29 June 2026, underscoring a relatively constrained price range in recent months.
Trading Metrics
| Metric | Value |
|---|---|
| Market Capitalisation | CNY 2.2 bn |
| Outstanding Shares | 372.5 mn |
| 24‑Hour Turnover | CNY 120.4 mn |
| 24‑Hour Volume | 20.7 mn shares |
| 24‑Hour % Change | –4.52 % vs. last month end |
| Price / Earnings (P/E) | Not disclosed |
| Price / Book (P/B) | Not disclosed |
Despite a modest decline in the month‑to‑month direction, the liquidity profile remains healthy, with a turnover of CNY 120.4 mn in the most recent trading window. The flat daily performance signals a consolidation phase, as the market digests recent earnings and regulatory updates.
Peer Benchmarking
The company’s contemporaries in the ophthalmic and broader pharmaceutical space displayed a range of dynamics:
| Stock | 24‑Hour % | Current Price | Market Cap | P/E |
|---|---|---|---|---|
| Ronshin (301231.SZ) | 0 % | CNY 31.00 | CNY 2.6 bn | — |
| Longli (300752.SZ) | 0 % | CNY 11.30 | CNY 2.6 bn | 90.37 |
| Senba (300701.SZ) | 0 % | CNY 9.26 | CNY 2.6 bn | 32.50 |
| Natural Food H (1837.HK) | +3.33 % | HKD 1.38 | HKD 3.1 bn | 8.21 |
| Ngl (002836.SZ) | 0 % | CNY 11.44 | CNY 2.6 bn | 70.89 |
The flat performance of Zhejiang Shapuaisi stands out against the modest gains of its peers, notably Natural Food H, which saw a 3.33 % uptick. However, the company’s valuation profile remains competitive, with a market cap aligned with its sector peers and a price that comfortably sits above the 200‑day average, suggesting potential upside if the stock can regain momentum.
Forward Outlook
Zhejiang Shapuaisi’s core product line—eye drops, infusion solutions, oral and topical formulations—positions it well within a growing ophthalmology market driven by aging demographics and increasing prevalence of chronic eye conditions. Recent product approvals and pipeline expansions, coupled with a strategic focus on cost‑efficient manufacturing, indicate that the firm is likely to benefit from both organic growth and incremental market share gains.
Key drivers to watch:
- Regulatory Approvals – Pending clearance of new formulations in key markets could provide a significant lift.
- Supply Chain Optimization – Recent investments in automation and logistics are expected to improve margins.
- Market Expansion – Targeting emerging markets in Southeast Asia may unlock new revenue streams.
With a solid market position and a clear strategy for scaling, Zhejiang Shapuaisi remains poised to capitalize on the expanding demand for ophthalmic solutions. Investors should monitor the next earnings cycle for confirmation of growth trajectories and assess the impact of any new product launches or regulatory milestones on the stock’s valuation trajectory.
